Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Flat Epithelia Atypia Intraductal Papilloma Without Atypia Women all races and ethnic groups are eligible for this trial. This trial is open to the accrual of women only Patients must be women Patients must be at least 18 years of age Patients must have an imaging abnormality that necessitated a core needle biopsy The imaging abnormality must have been categorized as Breast Imaging-Reporting and Data System (BIRADS) level 1-4 lesion There is documented concordance* between the initial breast imaging finding and the core biopsy pathology report. The core needle biopsy must contain FEA or IPWA, according to the local pathologist. (It is possible that the central pathology review which is done after the patient is registered on this protocol will have a diagnosis discrepant from that made by the original institution's pathologist. In that case, the study team will communicate this to the original institution's site investigator within one week of the date of the central pathology review having been finalized). Patients may have a personal history of prior or concurrent fibroadenoma and a prior history of proliferative breast lesions with or without atypia Patients must be registered on study within 100 days after core needle biopsy Patients must have an ability to understand and the willingness to sign a written informed consent document. The patient is still eligible for this study even if she declines consent for her tissue to be used for any (or all) of the correlative studies described in this document and/or if she declines consent for her tissue to go into a tissue bank for future unspecified research Concordance is a determination by the radiologist (or his or her covering provider) performing an image-guided core needle biopsy that the pathology report from this procedure corresponds to the imaging appearance of a given lesion and that the said lesion's most representative portion has been sampled  Personal history and/or concomitant diagnosis of invasive breast cancer or DCIS Palpable abnormality diagnosed by core needle biopsy to be FEA or IPWA Pathologic nipple discharge associated with IPWA (spontaneous bloody or clear persistent single duct discharge) A 5 lesion Discordance between the initial breast imaging finding and the core biopsy pathology report The presence of atypical ductal hyperplasia (ADH) on core biopsy Known current pregnancy. A pregnancy test is not required for this Women who are breastfeeding Patient registered on study more than 100 days since the date of core needle biopsy